Skip to main content
Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC) King, M., Stockler, M., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J., Buizen, L., Sjoquist, K., Gillies, K., Butow, P., Friedlander, M., GCIG Symptom Benefit Study Grp, Gynecologic Canc Intergrp GCIG SPRINGER. 2015: 22–23

View details for Web of Science ID 000361991100056